MedTrace Logo

Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer

NCT07313579 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-01-13

No results posted yet for this study

Summary

The study investigates the outcomes of hyperthermic intraperitoneal chemoperfusion (HIPEC) in combination with curative-intent gastrectomy in resectable locally-advanced and limited-metastatic (low peritoneal cancer index) gastric cancer.

Conditions

  • Gastric Cancer (GC)
  • HIPEC
  • Peritoneal Metastases From Gastric Cancer
  • Hyperthermic Intraperitoneal Chemoperfusion

Interventions

PROCEDURE

curative-intent surgery + HIPEC

Participants enrolled in this study will undergo curative-intent gastrectomy for gastric cancer, immediately followed by Hyperthermic Intraperitoneal Chemotherapy (HIPEC) performed during the same operative session. Dosage of drugs: mitomycin C 15 mg/m2, cisplatin 75mg/m2. The procedure is conducted according to a standardized protocol in National Cancer Institute

Sponsors & Collaborators

  • Ukrainian Society of Clinical Oncology

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2030-12-01
Completion
2035-12-01

Countries

  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07313579 on ClinicalTrials.gov